The Role of Combination or Co-formulation Products in the Treatment of Type 2 Diabetes (APhA2018)

The Role of Combination or Co-formulation Products in the Treatment of Type 2 Diabetes

Activity Preview

Most patients with type 2 diabetes will require multiple pharmacologic agents as their disease progresses. For second-line therapy and beyond, clinicians now select among several treatment options—including insulin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 agonists, and sodium–glucose cotransporter 2 inhibitors. Although combination or coformulation products can simplify treatment regimens, identifying the best therapies for individual patients can still be daunting. Come explore proven strategies for effective second-line therapies for type 2 diabetes.

Learning Objectives

After participating in this activity, the pharmacist will be able to:

  1. Review updates to the 2018 American Diabetes Association Standards of Medical Care in Diabetes related to the use of combination therapy or co-formulated products.
  2. Describe the evidence that supports a physiologic approach to treatment intensification using combination or co-formulation products
  3. Discuss contraindications and side effect considerations when recommending co-formulated therapy for glycemic control.
  4. Given a patient case, select among available co-formulation treatment options for add-on therapy.

    Activity type: Application-based

    Learning level: 2

    Audience: Pharmacists 

    Accreditation Information

    The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This activity is approved for 2.0 contact hours of CPE credit (0.20 CEUs). The ACPE Universal Activity Numbers for this activity is 0202-0000-18-053-H01-P.  

    To obtain credit for "The Role of Combination or Co-formulation Products in the Treatment of Type 2 Diabetes," complete the assessment with a grade of 70% or better, evaluation questions, and CLAIM credit. Participants will need to have a valid username and password to claim credit. After your credit has been claimed, please visit CPE monitor for your transcript.

    APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education examination. Please note that you will not be permitted to submit the examination a third time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.

    Individuals who participated in the live version of this activity held March 18, 2018, in Nashville, Tennesse may NOT receive credit for the home-study version of this activity.

    Initial release date: March 18, 2018
    Expiration date: March 18, 2021 NO CREDIT GRANTED AFTER THIS DATE


    "Direct Oral Anticoagulants: Determining Proper Use and Dose” is a home-study continuing education activity for pharmacists developed by the American Pharmacists Association.


    Brent Reed, BS, PHARMD and Toby Trujillo declare no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria.

    Conflicts of interest have been resolved through content review by Helen Sairany, PharmD, BCACP, Associate Director of Content Development at the American Pharmacists Association.

    System Requirements

    Computer and internet access are required to complete this activity.  Please visit our website to view the Technology System Requirements to have a positive learning experience.